Zabofloxacin

Zabofloxacin

Names
IUPAC name 1-Cyclopropyl-6-fluoro-7-[(8E)-8-(methoxyimino)-2,6-diazaspiro[3.4]oct-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Other names DW-224a
Identifiers
CAS Number	219680-11-2
ChemSpider	8128482
Jmol interactive 3D	Image
PubChem	9952872
InChI InChI=1S/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14- Key: ZNPOCLHDJCAZAH-UCQKPKSFSA-N InChI=1/C19H20FN5O4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21H,2-3,6-9H2,1H3,(H,27,28)/b23-14- Key: ZNPOCLHDJCAZAH-UCQKPKSFBL
SMILES Fc1c(nc2c(c1)C(=O)C(\C(=O)O)=C/N2C3CC3)N5C\C(=N\OC)C4(CNC4)C5
Properties
Chemical formula	C19H20FN5O4
Molar mass	401.392
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Zabofloxacin is an investigational fluoroquinolone antibiotic for multidrug-resistant infections due to Gram-positive bacteria.^[1][2][3] It also has activity against Neisseria gonorrhoeae including strains that are resistant to other quinolone antibiotics.^[4]

Zabofloxacin was discovered by Dong Wha Pharmaceuticals and licensed to Pacific Beach BioSciences for development.^[5]

References

1. HyeKyung Han, Sung Eun Kim, Kwang-Hee Shin, Cheolhee Lim, Kyoung Soo Lim, Kyung-Sang Yu, Joo-Youn Cho (October 2013). "Comparison of pharmacokinetics between new quinolone antibiotics: the zabofloxacin hydrochloride capsule and the zabofloxacin aspartate tablet". Current Medical Research and Opinion 29 (10): 1349–1355. doi:10.1185/03007995.2013.825591.
2. Jong-Hwa Lee, Jung-Heun Ha, Dae-Hun Park, Dong-Rack Choi, Gye-Won Lee, Sung-Hoon Ahn, and Choong-Yong Kim (2014). "Quantification Of Zabofloxacin In Rat Plasma Using Hplc-Uv Detector And Its Application To A Pharmacokinetic Study". Journal of Liquid Chromatography & Related Technologies 37 (3): 311–320. doi:10.1080/10826076.2012.745137.
3. Kim EJ, Shin WH, Kim KS, Han SS (Nov 2004). "Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent". Drug Chem Toxicol 27 (4): 295–307. doi:10.1081/DCT-200039708. PMID 15573468.
4. Jones RN, Biedenbach DJ, Ambrose PG, Wikler MA (2008). "Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains". Diagn Microbiol Infect Dis 62 (1): 110–112. doi:10.1016/j.diagmicrobio.2008.05.010. PMID 18620833.
5. "Pacific Beach BioSciences and Dong Wha Pharmaceuticals Sign Exclusive License Agreement to Develop and Commercialize Zabofloxacin (PB-101, DW-224a)". GlobeNewswire. August 10, 2007.

External links

• A Phase 2, Multi-dose, Double-Blind, Randomized, Multicenter, Safety and Efficacy Study of Zabofloxacin vs Moxifloxacin in the Treatment of Mild to Moderate Community-Acquired Pneumonia